| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Income (loss) from discontinued operations, net of income taxes | 102 | 6 | -17 | -42 |
| Net income (loss) | 152 | 551 | -653 | -609 |
| Net income (loss) per common share, basic (in dollars per share) | 0.01 | 0.05 | -0.06 | -0.05 |
| Net income (loss) per common share, diluted (in dollars per share) | 0.01 | 0.05 | -0.06 | -0.05 |
| Weighted average common shares, basic (in shares) | 11,574,000 | 11,574,000 | 11,552,000 | 11,532,000 |
| Weighted average common shares, diluted (in shares) | 11,574,000 | 11,574,000 | 11,552,000 | 11,532,000 |
TherapeuticsMD, Inc. (TXMD)
TherapeuticsMD, Inc. (TXMD)